Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

Osimertinib In EGFR Mutant Lung Cancer

Primary Outcome Measures Mechanisms of resistance to Osimertinib [ Time Frame: 4 Months ] Evaluated by comparing the genomic changes using targeted next generation sequencing in the post-osimertinib tumor to the pre-treatment tumor specimen. Secondary Outcome Measures Best objective response [ Time Frame: 6 months ] Best objective response will be evaluated via RECIST 1.1 criteria. RECIST1.1 measurements of ... [More >>]

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

Primary Outcome Measures Progression free survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Secondary Outcome Measures Overall survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Safety analysis (AEs according to CTCAE version ... [More >>]

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Primary Outcome Measures Phase I: Maximum Tolerated Dose (MTD) [ Time Frame: 9 Months ] Establish MTD of plinabulin in combination with nivolumab and ipilimumab for patients with recurrent SCLC Phase II: Progression-Free Survival (PFS) [ Time Frame: 36 Months ] Determine if the addition of plinabulin to double checkpoint inhibition (PD-1 and CTLA-4) ... [More >>]

Hybrid APC Therapy in Early Central Lung Cancer

Primary Outcome Measures Successful remission rate: [ Time Frame: 3 months ] successful remission is defined as absence of intraepithelial neoplasia in biopsies of original locations at 3 months after HybridAPC upon follow up Secondary Outcome Measures Complications [ Time Frame: 3 months ] possible complications include perforation, bleeding, fever, stenosis, cough and etc. Eligibility Criteria Inclusion Criteria Bronchoscopy and fluorescence bronchoscopy ... [More >>]

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed (IPPEM)

Primary Outcome Measures Association between PPI consumption and pemetrexed-related hematological toxicity (grade ≥ 3) [ Time Frame: Day 0 ] The hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria Eligibility Criteria Inclusion Criteria Patients who receive a pemetrexed-based chemotherapy regimen for the treatment of non-small cell ... [More >>]

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Primary Outcome Measures Efficacy [ Time Frame: 6 weeks (Arm B) or 8 weeks (Arm C) ] The fraction of evaluable patients who experience a PR or CR will be determined and this fraction will be reported along with an 80% and 95% confidence interval. Secondary Outcome Measures Safety [ Time Frame: 21 days (Arm B) or 28 days (Arm C) ] Safety ... [More >>]

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)

Primary Outcome Measures Safety [ Time Frame: up to 90 days after end of study treatment ] The proportion of patients experiencing treatment-related grade 3-4 adverse events (AEs) according to NCI-CTCAE criteria, version 4.0. PD-L1 expression induction by the treatment [ Time Frame: up to 24 months ] Proportion of patients showing PD-L1 expression ... [More >>]

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Primary Outcome Measures Number of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to 12 months ] TEAE defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. Secondary Outcome Measures Cmax of INCAGN02385 [ Time Frame: Up to 12 months ] Maximum observed ... [More >>]

Olaparib in People With Malignant Mesothelioma

Primary Outcome Measures Objective response rate [ Time Frame: 6 months after enrollment of last patient ] Percentage of subjects overall who experienced partial or complete response. Percentage of subjects with germline DNA repair mutation who experienced partial or complete response. Percentage of subjects with BAP1 somatic mutations who experienced partial or ... [More >>]

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Primary Outcome Measures Progression-free survival (PFS) [ Time Frame: Approximately 13 months ] Defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to ... [More >>]

Last update: January 19, 2018. 04:57:31 pm.